{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:22Z","timestamp":1740126442549,"version":"3.37.3"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,25]]},"abstract":"<jats:p>Prevention of recurrences of erythema multiforme is a therapeutic challenge. Thalidomide is effective, but its use is limited by adverse effects, especially peripheral neuropathy. We report seven cases of recurrent severe erythema multiforme treated with lenalidomide. In six cases, the drug was effective without significant adverse effects.<\/jats:p>","DOI":"10.1093\/ced\/llad314","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T18:31:21Z","timestamp":1694197881000},"page":"166-168","source":"Crossref","is-referenced-by-count":0,"title":["Prevention of recurrent erythema multiforme with lenalidomide: a case series"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-7096","authenticated-orcid":false,"given":"Saskia","family":"Ingen-Housz-Oro","sequence":"first","affiliation":[{"name":"Dermatology Department"},{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL) , Cr\u00e9teil, France"},{"name":"University Paris Est Cr\u00e9teil Val de Marne EpiDermE , Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL) , Cr\u00e9teil, France"},{"name":"Dermatology Department, Charles Nicolle University Hospital , Rouen , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willy","family":"Kini-Matondo","sequence":"additional","affiliation":[{"name":"Pharmacy, AP-HP, Henri Mondor Hospital , Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-5270","authenticated-orcid":false,"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Dermatology Department"},{"name":"Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL) , Cr\u00e9teil, France"},{"name":"University Paris Est Cr\u00e9teil Val de Marne EpiDermE , Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"2024012519205245400_llad314-B1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cden.2013.07.001","article-title":"Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment","volume":"57","author":"Samim","year":"2013","journal-title":"Dent Clin North Am"},{"key":"2024012519205245400_llad314-B2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/1523-1747.ep12338566","article-title":"Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major","volume":"106","author":"Foedinger","year":"1996","journal-title":"J Invest Dermatol"},{"key":"2024012519205245400_llad314-B3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.16928","article-title":"A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices","volume":"179","author":"Kechichian","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024012519205245400_llad314-B4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jdv.15447","article-title":"Interventions for erythema multiforme: a systematic review","volume":"33","author":"de Risi-Pugliese","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2024012519205245400_llad314-B5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jamadermatol.2021.4083","article-title":"Evaluation of thalidomide treatment of patients with chronic erythema multiforme: a multicenter retrospective cohort study","volume":"157","author":"Roux","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2024012519205245400_llad314-B6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamadermatol.2017.5889","article-title":"Lenalidomide as an alternative to thalidomide for treatment of recurrent erythema multiforme","volume":"154","author":"Drahy","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024012519205245400_llad314-B7","first-page":"375","article-title":"Dapsone in the treatment of persistent erythema multiforme","volume":"5","author":"Hoffman","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"2024012519205245400_llad314-B8","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/jdv.13313","article-title":"Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases","volume":"30","author":"Hirsch","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024012519205245400_llad314-B9","doi-asserted-by":"crossref","first-page":"R265","DOI":"10.1186\/ar4111","article-title":"Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus","volume":"14","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"Suppl.\u00a01","key":"2024012519205245400_llad314-B10","doi-asserted-by":"crossref","first-page":"\u200b1","DOI":"10.1007\/s12325-010-0104-8","article-title":"Management of the adverse\u00a0effects of lenalidomide in multiple myeloma","volume":"28","author":"Gonz\u00e1lez Rodr\u00edguez","year":"2011","journal-title":"Adv Ther"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad314\/53710568\/llad314.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/2\/166\/56420887\/llad314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/2\/166\/56420887\/llad314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T19:21:10Z","timestamp":1706210470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/2\/166\/7264816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":10,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,9,8]]},"published-print":{"date-parts":[[2024,1,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad314","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,9,8]]}}}